The treatment success rate for patients with multidrug-resistant tuberculosis (MDR TB) in the US is forecasted to increase from 79% in 2024 to 81% by 2028. This represents a modest upward trend with a projected year-on-year increase of around 0.5% to 1% starting in 2026. In 2023, the treatment success rate stood at 78%, making the compounded annual growth rate (CAGR) approximately 0.76% over the five-year period up to 2028.

Future trends to watch for include:

Advancements in treatment protocols and new drug developments which may further enhance success rates.
Increased accessibility to comprehensive care programs that can improve patient compliance and outcomes.
Potential policy interventions aimed at combating MDR TB, contributing to more substantial improvements in success rates.